Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease

Trial Profile

GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COR-388 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms GAIN
  • Sponsors Cortexyme
  • Most Recent Events

    • 12 Nov 2019 According to an Cortexyme media release, top-line results from the trial expected in the fourth quarter of 2021. The company is evaluating the feasibility of conducting an interim analysis.
    • 01 Nov 2019 According to a Cortexyme media release, data from this trial will be presented at the Clinical Trials on Alzheimer Disease (CTAD) 2019 on December 4-7, 2019 in San Diego.
    • 26 Sep 2019 According to an Cortexyme media release, the company announced the start of screening of patients in Europe.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top